DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,144,585
|Title:||Isolated mesenchymal progenitor cells and extracellular matrix produced thereby|
|Abstract:||Provided are methods of isolating an extracellular matrix from mesenchymal progenitor cells which are characterized by a reduced differentiation ability into an adipogenic lineage as compared to adipose-derived mesenchymal stem cells. Also provide isolated extracellular matrix and hybrid devices comprising electrospun elements and extracellular matrix which can be used for various tissue regeneration, repair and reconstruction surgeries.|
|Inventor(s):||Itskovitz-Eldor; Joseph (Haifa, IL), Shtrichman; Ronit (Haifa, IL), Zussman; Eyal (Haifa, IL), Barak; Efrat (Nofit, IL)|
|Assignee:||Technion Research & Development Foundation Limited (Haifa, IL)|
|Patent Claims:||1. A method of isolating an extracellular matrix, comprising: (a) obtaining induced pluripotent stem cells (iPSCs) derived from plucked human hair follicle keratinocytes
(HFKTs); (b) generating embryoid bodies (EBs) from said iPSCs; (c) generating single cells from adherent cells of said EBs, and (d) culturing said single cells in a culture medium which comprises ascorbic acid and does not comprise dexamethasone to
thereby obtain a population of mesenchymal progenitor cells which comprises at least 70% CD105+ cells, wherein said mesenchymal progenitor cells exhibit at least 70% reduced differentiation potential into an adipogenic lineage as compared to
differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions as analyzed after 28-30 days of culturing in a medium which comprises 10.sup.-6 M dexamethasone and indomethacin; and subsequently, (e) culturing
said mesenchymal progenitor cells produced in step (d) under conditions which induce production of extracellular matrix from said mesenchymal progenitor cells, and subsequently, (f) isolating the extracellular matrix produced by said mesenchymal
progenitor cells, thereby isolating the extracellular matrix.
2. The method of claim 1, further comprising decellularizing said extracellular matrix.
3. The method of claim 1, wherein said single cells from adherent cells of said EBs are obtained by: (a) dissociating the EBs to cell aggregates, (b) culturing said cell aggregates on a low-adhesive surface so as to select a population of adherent cells, and (c) dissociating said adherent cells to single cells.
4. The method of claim 1, wherein said EBs are 8-14 day-old human EBs.
5. The method of claim 3, wherein each of said aggregates comprises about 10-30 cells.
6. The method of claim 3, wherein said dissociating said EBs into said aggregates is effected using Collagenase B.
7. The method of claim 3, wherein said adherent cells are expanded by at least 2 fold within 2-3 days of culturing in said culture medium.
8. The method of claim 1, wherein differentiation into an osteogenic lineage of said mesenchymal progenitor cells is increased by at least 50% as compared to differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions.
9. The method of claim 1, wherein said culturing in step (e) is performed on an electrospun element.
10. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are CD105+/CD90+.
11. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD90+/CD73+/CD44+/CD29+ signature.
12. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD45-/CD34- signature.
13. The method of claim 1, wherein said mesenchymal progenitor cells maintain the ability to form extracellular matrix for at least 8 passages.
14. The method of claim 1, wherein said culturing in step (d) is performed for 1-15 passages.
15. The method of claim 1, wherein said iPSCs are lentiviral vector-free iPSCs.
Summary for Patent: Start Trial
|PCT Filed||July 27, 2011||PCT Application Number:||PCT/IL2011/000604|
|PCT Publication Date:||February 02, 2012||PCT Publication Number:||WO2012/014205|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Advance Biofactures||SANTYL||collagenase||VIAL||101995||001||1965-06-04||Start Trial||Technion Research & Development Foundation Limited (Haifa, IL)||2030-07-27||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2012014205||Feb 02, 2012|
|World Intellectual Property Organization (WIPO)||2012014207||Feb 02, 2012|
|World Intellectual Property Organization (WIPO)||2012014207||Jul 12, 2012|
|United States of America||2013130387||May 23, 2013|
|United States of America||2013230601||Sep 05, 2013|
|Japan||2013535966||Sep 19, 2013|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.